SciSparc (SPRC) Interest Expenses (2016 - 2024)

SciSparc (SPRC) posted Interest Expenses of $2.4 million for Q2 2024, up 22.71% sequentially from $2.0 million in Q4 2022.

SciSparc (SPRC) Interest Expenses (2016 - 2024) Analysis & Trends

SciSparc has reported Interest Expenses for 6 years, with the latest figure at $2.4 million in Q2 2024.

Quarterly Interest Expenses changed N/A year-over-year to $2.4 million in Q2 2024, while the trailing twelve-month figure through Dec 2024 was $2.0 million (up 81.2% YoY) and the FY2025 annual result came in at $8.2 million, up 1014.05% from the prior year.
Interest Expenses grew to $2.4 million in Q2 2024 per SPRC's latest filing, from $2.0 million in the prior quarter.
Over five years, Interest Expenses peaked at $2.4 million in Q2 2024 and troughed at -$894000.0 in Q3 2022.
A 3-year average of $1.2 million and a median of $1.6 million in 2020 frame the typical range for Interest Expenses.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	11.00 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	39.74 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	82.05 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	20.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	93.62 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-4.89 Mn
10	SciSparc	836,385.99	836,385.99	-	-

Download Data